Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- GRI
- Price
- 2.31
- Stock movement up
- +- (0.00%)
- Company name
- GRI Bio Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.34M
- Ent value
- -2.23M
- Price/Sales
- 0.12
- Price/Book
- 0.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -53.18%
- 1 year return (CAGR)
- -84.72%
- 3 year return (CAGR)
- -95.17%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GRI does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.12 |
| Price to Book | 0.56 |
| EV to Sales | -0.08 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.45M |
| EPS (TTM) | -24.02 |
| FCF per share (TTM) | -21.27 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 28.87M |
| Gross profit (TTM) | -4.00K |
| Operating income (TTM) | -11.98M |
| Net income (TTM) | -11.96M |
| EPS (TTM) | -24.02 |
| EPS (1y forward) | -12.60 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -0.01% |
| Operating margin (TTM) | -41.48% |
| Profit margin (TTM) | -41.41% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 8.23M |
| Net receivables | 0.00 |
| Total current assets | 8.59M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 108.00K |
| Total assets | 8.67M |
| Accounts payable | 1.84M |
| Short/Current long term debt | 71.00K |
| Total current liabilities | 2.64M |
| Total liabilities | 2.66M |
| Shareholder's equity | 6.01M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.19M |
| Capital expenditures (TTM) | 399.00K |
| Free cash flow (TTM) | -10.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -199.00% |
| Return on Assets | -137.96% |
| Return on Invested Capital | -197.16% |
| Cash Return on Invested Capital | -174.55% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.26 |
| Daily high | 2.41 |
| Daily low | 2.17 |
| Daily Volume | 59K |
| All-time high | 739939.20 |
| 1y analyst estimate | 644.00 |
| Beta | -1.23 |
| EPS (TTM) | -24.02 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GRI | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.82% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 17 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -84.57% | -10.84% |
| Avg time to new high | 158 days | 12 days |
| Max time to new high | 1114 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.34M
Marketcap category
Small-cap
Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Employees
3
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page